Sai Life Sciences Reports Strong Q2 FY27 With Revenue Up 23% YoY
Sai Life Sciences Ltd · Investor Presentation · 06 Nov 2026, 5:47 am
Sai Life Sciences Reports Strong Q2 FY27 With Revenue Up 23% YoY Sai Life Sciences posted consolidated revenue of ₹659 Cr in Q2 FY27, up 23% YoY, with EBITDA reaching ₹187 Cr (28% margin) and PAT rising 17% YoY to ₹98 Cr. CDMO and CRO accounted for 64% and 36% of quarterly revenues, respectively, with capacity utilization at 67%. For H1 FY27, revenue climbed 17% YoY to ₹1,213 Cr, with EBITDA at ₹335 Cr and PAT of ₹172 Cr. Capex reached ₹621 Cr in H1 FY27, staying on track for the full-year target of ₹1,100–1,300 Cr.
Original exchange filing (PDF)
More announcements from Sai Life Sciences Ltd
- Upgradation in the Credit Rating by India Rating & Research Pvt. Ltd. · 14 Nov 2026
- Transcripts of Earnings call organized on 06th November 2026 · 12 Nov 2026
- Monitoring Agency Report for the Quarter ended 30th September 2026 · 12 Nov 2026
- Audio Recording of Earnings call for Q-2 FY 2026-27 · 06 Nov 2026
- Press Release on Unaudited Financial Results for the Second Quarter and Half Year Ended 30th September 2026. · 06 Nov 2026
- Allotment of 1,08,005 Equity having Face Value of Rs.1/- against the options exercised in accordance with the Companies ESOP Plans · 06 Nov 2026
- Sai Life Sciences Limited has informed the Exchange regarding Allotment of 108005 Shares. · 06 Nov 2026
- Change In Management - Appointment of SMPs · 06 Nov 2026
